sotevtamab   Click here for help

GtoPdb Ligand ID: 11763

Synonyms: 16B5 [1] | AB-16B5 | AB-sCLU mAb | AB16B5
Compound class: Antibody
Comment: Sotevtamab (AB-16B5) is a humanized IgG2 antibody against secreted clusterin. It was developed by Alethia Biotherapeutics for anti-cancer potential. Peptide sequences of the heavy and light chains of the antibody are claimed in patent WO2011063523A1 [1], via which sotevtamab can be linked to the antibody designated as humanised 16B5. Sotevtamab is expected to inhibit clusterin-induced epithelial to mesenchymal transition, as a mechanism to both reduce tumour invasion and augment the response to standard of care chemotherapy.
Click here for help
1. Tremblay GB, Filion M, Sulea T. (2011)
Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume.
Patent number: WO2011063523A1. Assignee: Alethia Biotherapeutics Inc., National Research Council Of Canada. Priority date: 24/11/2009. Publication date: 03/06/2011.